
Jean-Louis Excler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5488494/publications.pdf Version: 2024-02-01



IEAN-LOUIS EXCLED

#	Article	IF	CITATIONS
1	Initiation of ART during Early Acute HIV Infection Preserves Mucosal Th17 Function and Reverses HIV-Related Immune Activation. PLoS Pathogens, 2014, 10, e1004543.	4.7	218
2	Vaccine development for emerging infectious diseases. Nature Medicine, 2021, 27, 591-600.	30.7	213
3	Lessons from the RV144 Thai Phase III HIV-1 Vaccine Trial and the Search for Correlates of Protection. Annual Review of Medicine, 2015, 66, 423-437.	12.2	150
4	The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics. Clinical Infectious Diseases, 2019, 69, 877-883.	5.8	122
5	HIV vaccines: lessons learned and the way forward. Current Opinion in HIV and AIDS, 2010, 5, 428-434.	3.8	118
6	Nonneutralizing Functional Antibodies: a New "Old―Paradigm for HIV Vaccines. Vaccine Journal, 2014, 21, 1023-1036.	3.1	107
7	A Phase I Double Blind, Placebo-Controlled, Randomized Study of a Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults. PLoS ONE, 2012, 7, e41936.	2.5	74
8	Efficacy of a single-dose regimen of inactivated whole-cell oral cholera vaccine: results from 2 years of follow-up of a randomised trial. Lancet Infectious Diseases, The, 2018, 18, 666-674.	9.1	69
9	Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial. Journal of Infectious Diseases, 2017, 215, 1255-1263.	4.0	57
10	Current and future cholera vaccines. Vaccine, 2020, 38, A118-A126.	3.8	57
11	Stakeholder Engagement in HIV Cure Research: Lessons Learned from Other HIV Interventions and the Way Forward. AIDS Patient Care and STDs, 2015, 29, 389-399.	2.5	54
12	A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Subtype C-Modified Vaccinia Ankara Virus Vaccine Candidate in Indian Volunteers. AIDS Research and Human Retroviruses, 2009, 25, 1107-1116.	1.1	53
13	Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand. PLoS ONE, 2011, 6, e27837.	2.5	48
14	A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Subtype C Adeno-Associated Virus Vaccine. AIDS Research and Human Retroviruses, 2008, 24, 873-880.	1.1	43
15	Safety and Immunogenicity of DNA and MVA HIV-1 Subtype C Vaccine Prime-Boost Regimens: A Phase I Randomised Trial in HIV-Uninfected Indian Volunteers. PLoS ONE, 2013, 8, e55831.	2.5	41
16	Review on the Recent Advances on Typhoid Vaccine Development and Challenges Ahead. Clinical Infectious Diseases, 2020, 71, S141-S150.	5.8	41
17	Heterologous Prime-Boost Regimens Using rAd35 and rMVA Vectors Elicit Stronger Cellular Immune Responses to HIV Proteins Than Homologous Regimens. PLoS ONE, 2012, 7, e45840.	2.5	40
18	Novel directions in HIV-1 vaccines revealed from clinical trials. Current Opinion in HIV and AIDS, 2013, 8, 421-431.	3.8	39

2

JEAN-LOUIS EXCLER

#	Article	IF	CITATIONS
19	Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens. AIDS Research and Human Retroviruses, 2017, 33, 410-423.	1.1	38
20	First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus–Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens. Journal of Infectious Diseases, 2017, 215, 95-104.	4.0	38
21	Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. PLoS Pathogens, 2017, 13, e1006182.	4.7	38
22	Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children. Vaccine, 2018, 36, 3794-3801.	3.8	36
23	The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform. Vaccine, 2021, 39, 3067-3080.	3.8	36
24	Novel prime-boost vaccine strategies against HIV-1. Expert Review of Vaccines, 2019, 18, 765-779.	4.4	34
25	Comparative safety of mRNA COVIDâ€19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database. Journal of Medical Virology, 2022, 94, 1085-1095.	5.0	34
26	Vaccines to prevent transmission of HIV-1 via breastmilk: scientific and logistical priorities. Lancet, The, 2006, 368, 511-521.	13.7	33
27	Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial. Lancet HIV,the, 2020, 7, e238-e248.	4.7	33
28	Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains. Vaccine, 2016, 34, 6610-6616.	3.8	32
29	HIV-1 vaccines. Human Vaccines and Immunotherapeutics, 2014, 10, 1734-1746.	3.3	30
30	Prospects for a Globally Effective HIV-1 Vaccine. American Journal of Preventive Medicine, 2015, 49, S307-S318.	3.0	29
31	Lessons learnt from 12 oral cholera vaccine campaigns in resource-poor settings. Bulletin of the World Health Organization, 2017, 95, 303-312.	3.3	29
32	AIDS Vaccines and Preexposure Prophylaxis: Is Synergy Possible?. AIDS Research and Human Retroviruses, 2011, 27, 669-680.	1.1	28
33	The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development. Expert Review of Vaccines, 2014, 13, 1489-1500.	4.4	28
34	Prospects for a globally effective HIV-1 vaccine. Vaccine, 2015, 33, D4-D12.	3.8	28
35	Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: Implications for AIDS vaccine development using Sendai virus vectors. Hum Vaccin, 2011, 7, 639-645.	2.4	27
36	The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Vaccine, 2015, 33, 73-75.	3.8	26

JEAN-LOUIS EXCLER

#	Article	IF	CITATIONS
37	Spatial and Temporal Patterns of Typhoid and Paratyphoid Fever Outbreaks: A Worldwide Review, 1990–2018. Clinical Infectious Diseases, 2019, 69, S499-S509.	5.8	25
38	Supply and delivery of vaccines for global health. Current Opinion in Immunology, 2021, 71, 13-20.	5.5	25
39	Lessons from HIV-1 vaccine efficacy trials. Current Opinion in HIV and AIDS, 2016, 11, 607-613.	3.8	21
40	Development of Middle East Respiratory Syndrome Coronavirus vaccines – advances and challenges. Human Vaccines and Immunotherapeutics, 2018, 14, 304-313.	3.3	21
41	The US Military Commitment to Vaccine Development: A Century of Successes and Challenges. Frontiers in Immunology, 2018, 9, 1397.	4.8	21
42	Toward Developing a Preventive MERS-CoV Vaccine—Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14–15, 2015. Emerging Infectious Diseases, 2016, 22, .	4.3	20
43	Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency. Journal of Virology, 2020, 94, .	3.4	19
44	Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines. Vaccine, 2019, 37, 5796-5802.	3.8	18
45	HIV vaccine delayed boosting increases Env variable region 2–specific antibody effector functions. JCI Insight, 2020, 5, .	5.0	18
46	A strategy for accelerating the development of preventive AIDS vaccines. Aids, 2007, 21, 2259-2263.	2.2	16
47	Accelerating the development of a group A <i>Streptococcus</i> vaccine: an urgent public health need. Clinical and Experimental Vaccine Research, 2016, 5, 101.	2.2	16
48	Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine. PLoS ONE, 2019, 14, e0211784.	2.5	16
49	Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene. Journal of Infectious Diseases, 2016, 213, 1946-1954.	4.0	14
50	Molecular epidemiology of a primarily MSM acute HIVâ€1 cohort in Bangkok, Thailand and connections within networks of transmission in Asia. Journal of the International AIDS Society, 2018, 21, e25204.	3.0	14
51	Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations. PLoS ONE, 2018, 13, e0196397.	2.5	14
52	Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report. Vaccine, 2020, 38, 4476-4483.	3.8	14
53	Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study. EClinicalMedicine, 2020, 27, 100540.	7.1	14
54	Broad HIV Epitope Specificity and Viral Inhibition Induced by Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults. PLoS ONE, 2014, 9, e90378.	2.5	13

JEAN-LOUIS EXCLER

#	Article	IF	CITATIONS
55	HIV Vaccine Efficacy and Immune Correlates of Risk. Current HIV Research, 2014, 11, 450-463.	0.5	13
56	Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. PLoS ONE, 2017, 12, e0176428.	2.5	12
57	An overview of Vaxchora TM , a live attenuated oral cholera vaccine. Human Vaccines and Immunotherapeutics, 2020, 16, 42-50.	3.3	12
58	AIDS vaccine efficacy trials: expand capacity and prioritize. Expert Review of Vaccines, 2006, 5, 167-170.	4.4	11
59	HIV-specific Antibody in Rectal Secretions Following Late Boosts in RV144 Participants (RV305). AIDS Research and Human Retroviruses, 2014, 30, A33-A33.	1.1	11
60	HIV epidemic in Asia: optimizing and expanding vaccine development. Expert Review of Vaccines, 2012, 11, 805-819.	4.4	10
61	The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines. Vaccine, 2020, 38, 5556-5561.	3.8	9
62	Beyond RV144 Efficacy Results: An Update. Procedia in Vaccinology, 2013, 7, 49-56.	0.4	8
63	A randomized, observer-blinded, equivalence trial comparing two variations of Euvichol®, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the Philippines. Vaccine, 2018, 36, 4317-4324.	3.8	8
64	Augmented immune responses to a booster dose of oral cholera vaccine in Bangladeshi children less than 5Âyears of age: Revaccination after an interval of over three years of primary vaccination with a single dose of vaccine. Vaccine, 2020, 38, 1753-1761.	3.8	8
65	Recent Advances and Methodological Considerations on Vaccine Candidates for Human Schistosomiasis. Frontiers in Tropical Diseases, 2021, 2, .	1.4	8
66	Safety of a bivalent, killed, whole-cell oral cholera vaccine in pregnant women in Bangladesh: evidence from a randomized placebo-controlled trial. BMC Infectious Diseases, 2019, 19, 422.	2.9	7
67	Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection. Human Vaccines and Immunotherapeutics, 2015, 11, 1036-1037.	3.3	6
68	The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines. Vaccine, 2020, 38, 5734-5739.	3.8	6
69	Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines. Vaccine, 2020, 38, 7702-7707.	3.8	6
70	An HIV Vaccine for South-East Asia—Opportunities and Challenges. Vaccines, 2013, 1, 348-366.	4.4	5
71	Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events. Human Vaccines and Immunotherapeutics, 2012, 8, 630-638.	3.3	4
72	The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines. Vaccine, 2020, 38, 7708-7715.	3.8	4

#	Article	IF	CITATIONS
73	Expectation of Volunteers Towards the Vaccine Efficacy of the Prime-Boost HIV Vaccine Phase III Trial During Unblinding. AIDS Research and Human Retroviruses, 2014, 30, 1041-1045.	1.1	3
74	Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand. PLoS ONE, 2015, 10, e0127998.	2.5	2
75	Existing cost-effectiveness analyses for diseases caused by Group A Streptococcus: A systematic review to guide future research. Wellcome Open Research, 0, 6, 211.	1.8	2
76	A non-inferiority trial comparing two killed, whole cell, oral cholera vaccines (Cholvax vs.) Tj ETQq0 0 0 rgBT /Ov	erlock 10 3.8	Tf 50 622 Td (\$

77	HIV prevention & treatment - Reasons to rejoice & remain vigilant. Indian Journal of Medical Research, 2015, 142, 633.	1.0	1
78	HIV-vaccines: lessons learned and the way forward. Asian Biomedicine, 2010, 4, 683-690.	0.3	0
79	Late Boosting of the RV144 Regimen Improves the Magnitude and Quality of Immune Responses. SSRN Electronic Journal, 0, , .	0.4	0